AXPAXLI (OTX-TKI)
Wet Age-Related Macular Degeneration
Key Facts
About Ocular Therapeutix
Ocular Therapeutix's mission is to redefine the treatment of ophthalmic diseases by leveraging its proprietary hydrogel technology to create sustained-release therapies that reduce the high frequency of interventions required by current standards of care. The company has successfully transitioned to commercial operations with DEXTENZA® and is now on the cusp of a major value inflection with its lead candidate, AXPAXLI™ (axitinib implant), under FDA review for wet AMD. Its strategy centers on addressing the critical unmet need of treatment burden to improve patient adherence and visual outcomes, thereby capturing significant share in multi-billion dollar retinal markets.
View full company profileAbout Ocular Therapeutix
Ocular Therapeutix's mission is to redefine the treatment of ophthalmic diseases by leveraging its proprietary hydrogel technology to create sustained-release therapies that reduce the high frequency of interventions required by current standards of care. The company has successfully transitioned to commercial operations with DEXTENZA® and is now on the cusp of a major value inflection with its lead candidate, AXPAXLI™ (axitinib implant), under FDA review for wet AMD. Its strategy centers on addressing the critical unmet need of treatment burden to improve patient adherence and visual outcomes, thereby capturing significant share in multi-billion dollar retinal markets.
View full company profileAbout Ocular Therapeutix
Ocular Therapeutix's mission is to redefine the treatment of ophthalmic diseases by leveraging its proprietary hydrogel technology to create sustained-release therapies that reduce the high frequency of interventions required by current standards of care. The company has successfully transitioned to commercial operations with DEXTENZA® and is now on the cusp of a major value inflection with its lead candidate, AXPAXLI™ (axitinib implant), under FDA review for wet AMD. Its strategy centers on addressing the critical unmet need of treatment burden to improve patient adherence and visual outcomes, thereby capturing significant share in multi-billion dollar retinal markets.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Wet AMD Program | Exonate | Pre-clinical |
| AKST4290 | Alkahest | Phase 2 |
| 4D-150 | 4D Molecular Therapeutics | Phase 3 |